Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other financing activities: 2012-2024

Historic Other financing activities for Ligand Pharmaceuticals (LGND) over the last 5 years, with Dec 2024 value amounting to $426,000.

  • Ligand Pharmaceuticals' Other financing activities rose 6965.71% to $14.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 1095.62%. This contributed to the annual value of $426,000 for FY2024, which is 55.11% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Other financing activities stood at $426,000 for FY2024, which was down 55.11% from $949,000 recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Other financing activities registered a high of $949,000 during FY2023, and its lowest value of $426,000 during FY2024.
  • Over the past 2 years, Ligand Pharmaceuticals' median Other financing activities value was $687,500 (recorded in 2023), while the average stood at $687,500.
  • Data for Ligand Pharmaceuticals' Other financing activities shows a maximum YoY crashed of 55.11% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Ligand Pharmaceuticals' Other financing activities stood at $949,000 in 2023, then slumped by 55.11% to $426,000 in 2024.